New data from the pivotal trial elacestrant in patients with ER+/HER2- metastatic breast cancer show subgroups that get the greatest progression-free survival benefit.
New Orleans, Louisiana (PRWEB) April 09, 2022 NEW ORLEANS, La. Two Roswell Park Comprehensive Cancer Center oncologists will discuss promising strategies
New Orleans, Louisiana (PRWEB) April 09, 2022 Combining a beta-blocker with the cancer immunotherapy drug pembrolizumab could be a promising new treatment
Highlights More than 30 teams of Roswell Park specialists selected to present findings Highlights include plenary session, minisymposium and late-breaking abstracts Findings include research on new cancer drugs and new uses for beta blockers.